- Conditions
- Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
- Interventions
- ANSAR ANX 3.0 Software
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 9,514
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 117
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
- Conditions
- Infection
- Interventions
- 70% Isopropyl alcohol embedded caps, Usual Care
- Device · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Day to 35 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
- Conditions
- Growth
- Interventions
- Cow's milk protein infant formula, Partially hydrolyzed protein infant formula
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 10 Days to 14 Days
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Certolizumab pegol
- Other · Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Semaglutide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 57 more
- Conditions
- Gout
- Interventions
- Pegloticase, Azathioprine
- Biological · Drug
- Lead sponsor
- Ampel BioSolutions, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Wheaton, Maryland + 8 more
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Asthma
- Interventions
- QAW039 150 mg, QAW039 450 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Encinitas, California • Newport Beach, California + 41 more
- Conditions
- Focal Epilepsy
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 19 more
- Conditions
- Asthma
- Interventions
- Lansoprazole, Matching placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
- Conditions
- Pulmonary Embolism
- Interventions
- FlowTriever System, Anticoagulation Agents
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
- Biological · Drug
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more
- Conditions
- Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
- Interventions
- Conjugated Estrogens Cream, Placebo Cream
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 48 Years and older · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas
- Conditions
- Dermatitis, Atopic
- Interventions
- Protopic, Corticosteroid, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more
- Conditions
- Alzheimers Disease
- Interventions
- Trontinemab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
- Conditions
- Atrial Fibrillation New Onset
- Interventions
- CorMatrix ECM for Pericardial Closure
- Device
- Lead sponsor
- Elutia Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 12 more
- Conditions
- Vaginitis Trichomonal or Due to Trichomonas
- Interventions
- MTZ 500 mg twice daily x 7 days, MTZ 2 g
- Drug
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
- Drug · Radiation · Biological
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 760
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more
- Conditions
- Peripheral T-cell Lymphomas, Adult T-cell Leukemia, Adult T-cell Lymphoma, Peripheral T-cell Lymphoma Unspecified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, T/Null Cell Systemic Type, Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 129
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
- Conditions
- Sickle Cell Disease
- Interventions
- TAK-755, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more